Cargando…

Secukinumab for ankylosing spondylitis and psoriatic arthritis

The treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) positively changed since the introduction of anti-TNFα drugs. These treatments were shown to reduce the symptoms and signs of the diseases and improve the quality of life. However, a variable percentage of patients do not res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lubrano, Ennio, Perrotta, Fabio Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085310/ https://www.ncbi.nlm.nih.gov/pubmed/27799780 http://dx.doi.org/10.2147/TCRM.S100091

Ejemplares similares

Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis
por: Elliott, Ashley, et al.
Publicado: (2019)

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis
por: Elewski, Boni E., et al.
Publicado: (2021)

Therapeutic Targets for Ankylosing Spondylitis – Recent Insights and Future Prospects
por: Perrotta, Fabio Massimo, et al.
Publicado: (2022)

Drug Retention and Safety of Secukinumab in a Real-World Cohort of Ankylosing Spondylitis and Psoriatic Arthritis Patients
por: Moskal, Mateusz, et al.
Publicado: (2022)

Secukinumab: A Review in Ankylosing Spondylitis
por: Blair, Hannah A.
Publicado: (2019)

Difficult to Treat and Refractory to Treatment in Psoriatic Arthritis
por: Lubrano, Ennio, et al.
Publicado: (2023)

The “Climb” Towards Minimal Disease Activity in Psoriatic Arthritis
por: Lubrano, Ennio, et al.
Publicado: (2021)

Correction to: Secukinumab: A Review in Ankylosing Spondylitis
por: Blair, Hannah A.
Publicado: (2019)

Role of secukinumab in ankylosing spondylitis with tubercular uveitis
por: Mahendradas, Padmamalini, et al.
Publicado: (2020)

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative
por: Colombo, Giorgio L, et al.
Publicado: (2018)

Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab
por: Kiltz, Uta, et al.
Publicado: (2022)

New Insights in Physical Therapy and Rehabilitation in Psoriatic Arthritis: A Review
por: Perrotta, Fabio Massimo, et al.
Publicado: (2021)

A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
por: Cortesi, Paolo Angelo, et al.
Publicado: (2023)

A Review of the Use of Secukinumab for Psoriatic Arthritis
por: Patel, Nupur U., et al.
Publicado: (2017)

Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study
por: Perrotta, Fabio Massimo, et al.
Publicado: (2018)

Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives
por: Tahir, Hasan, et al.
Publicado: (2020)

Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
por: Emery, Paul, et al.
Publicado: (2018)

Effectiveness and safety of secukinumab in ankylosing spondylitis: real-life data from Midlands Ankylosing Spondylitis Collaboration (MASC)
por: Ajibade, Adeola, et al.
Publicado: (2023)

Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study
por: Kiltz, Uta, et al.
Publicado: (2020)

Psoriatic Arthritis in Males and Females: Differences and Similarities
por: Lubrano, Ennio, et al.
Publicado: (2023)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
por: Lubrano, Ennio, et al.
Publicado: (2019)

Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Ultrasonographic Evaluation of Entheseal Fibrocartilage in Patients with Psoriatic Arthritis, Athletes and Healthy Controls: A Comparison Study
por: Perrotta, Fabio Massimo, et al.
Publicado: (2023)

Clinical Characteristics of Potential “Difficult-to-treat” Patients with Psoriatic Arthritis: A Retrospective Analysis of a Longitudinal Cohort
por: Perrotta, Fabio Massimo, et al.
Publicado: (2022)

Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective
por: Lubrano, Ennio, et al.
Publicado: (2022)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
por: Ogdie, Alexis, et al.
Publicado: (2020)

Dactylitis and Early Onset Psoriasis in Psoriatic Arthritis: Are they Markers of Disease Severity? A Clinical Study
por: Scriffignano, Silvia, et al.
Publicado: (2022)

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
por: Deodhar, A., et al.
Publicado: (2019)

Correction to: Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Triple jump for the optimal management of psoriatic arthritis: diet, sleep and exercise – a review
por: Lubrano, Ennio, et al.
Publicado: (2023)

Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland
por: Purmonen, Timo, et al.
Publicado: (2019)

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
por: Schreiber, Stefan, et al.
Publicado: (2019)

Secular trends in sickness absence among Swedish patients with ankylosing spondylitis and psoriatic arthritis
por: Nielsen, Christel, et al.
Publicado: (2017)

Racial Differences in Prevalence and Treatment for Psoriatic Arthritis and Ankylosing Spondylitis by Insurance Coverage in the USA
por: Ogdie, Alexis, et al.
Publicado: (2021)

Associations of IL-18 with Altered Cardiovascular Risk Profile in Psoriatic Arthritis and Ankylosing Spondylitis
por: Bonek, Krzysztof, et al.
Publicado: (2022)

Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014)

Identification of the Minimal Disease Activity Domains Achieved Based on Different Treatments in Psoriatic Arthritis
por: Scriffignano, Silvia, et al.
Publicado: (2023)

Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
por: Deyab, Gia, et al.
Publicado: (2017)

MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
por: Charles-Schoeman, Christina, et al.
Publicado: (2023)

Golimumab: A novel human anti-TNF-α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
por: Kay, Jonathan, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_fo1djrppih2kjliom741tbm1cv